OXIS International names David Saloff as Chief Executive Officer

OXIS International names David Saloff as Chief Executive Officer

OXIS International, Inc. announced it has named David Saloff as Chief Executive Officer. Mr. Saloff was appointed to the Company's Board of Directors in June of 2011.


OXIS International, Inc. (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced it has named David Saloff as Chief Executive Officer. Mr. Saloff was appointed to the Company's Board of Directors in June of 2011.

"David's proven ability to move companies from development stage to successful commercialization makes him an outstanding choice to lead OXIS at this time," said Anthony J. Cataldo, Chairman of OXIS International. "In addition to his managerial experience, David has an outstanding track record of effectively raising and deploying capital, and building shareholder value."

Mr. Saloff stated, "OXIS International can become a leader in the nutraceutical and nutritional food industry by leveraging the unique properties and benefits of Ergothioneine, one of the most potent and versatile antioxidants yet discovered. I look forward to working with OXIS' strong network of scientific advisors and marketing partners to continue the development and commercialization of our ERGO-based products."

Mr. Saloff is a successful entrepreneur in the healthcare industry, having founded three companies, two of which went public and a third that was sold to a leading healthcare products company. In 1991, he founded Electropharmacology, which developed first-generation solid state pulse electromagnetic field therapy devices to treat chronic wounds. Later he assumed the Presidency of LifeWaves International, a health and fitness research and development company based on a revolutionary exercise and lifestyle theory to increase longevity. He also was co-founder and co-chief executive officer of Ivivi Technologies, which developed and manufactured advanced non-drug anti-inflammatory devices for the treatment of chronic and acute wounds and post-surgical pain.

About OXIS International, Inc.

OXIS International, Inc. is a long-established but recently revitalized biotechnology Company developing multiple proprietary, natural substance-based products focused on oxidative stress and inflammation, which are associated with the negative effects of free radicals and reactive oxygen species. The Company's consumer product portfolio includes dietary supplements and is expected ultimately to include functional foods and beverages, skin care and other personal care products, and animal health products. Specifically, OXIS is emphasizing the unique properties of L-Ergothioneine, a highly potent, patent-protected and versatile antioxidant. The Company has completed a strategic financing agreement with its primary product development and manufacturing partner, Gemini Pharmaceuticals, launched its first product, ErgoFlex for joint pain relief and overall joint health, and announced a joint venture with engage:BDR, a global leader in online sales and marketing. For more information, please visit www.oxis.com.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish